{"id":960941,"date":"2026-05-11T16:36:18","date_gmt":"2026-05-11T20:36:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/"},"modified":"2026-05-11T16:36:18","modified_gmt":"2026-05-11T20:36:18","slug":"savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/","title":{"rendered":"Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference"},"content":{"rendered":"

<\/p>\n

Savara Announces Participation in the H.C. Wainwright & Co. 4th<\/sup> Annual BioConnect Investor Conference<\/b><\/p>\n

LANGHORNE, Pa.–(BUSINESS WIRE<\/a>)–Savara Inc.<\/a> (Nasdaq: SVRA<\/a>) (the \u201cCompany\u201d), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright & Co. 4th<\/sup> Annual BioConnect Investor Conference on Tuesday, May 19th<\/sup> at 10:00am ET in New York, NY at the NASDAQ headquarters.<\/p>\n

\nThe live webcast and subsequent replay will be available on the \u201cEvents & Presentations\u201d<\/a> section of the Company\u2019s corporate website and will be archived for 90 days.<\/p>\n

About Savara<\/b><\/a><\/p>\n

\nSavara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary investigational eFlow\u00ae<\/sup> Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com<\/a> and LinkedIn<\/a>.<\/p>\n

*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.<\/i><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260511376114\/en\/<\/a><\/span><\/p>\n

Media and Investor Relations Contact
\n<\/span><\/b>
Savara Inc.
\n
Temre Johnson, Executive Director, Corporate Affairs
\n
ir@savarapharma.com<\/a><\/p>\n

KEYWORDS:<\/b> Pennsylvania New York United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference LANGHORNE, Pa.–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA) (the \u201cCompany\u201d), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference on Tuesday, May 19th at 10:00am ET in New York, NY at the NASDAQ headquarters. The live webcast and subsequent replay will be available on the \u201cEvents & Presentations\u201d section of the Company\u2019s corporate website and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant … <\/p>\n

Continue reading “Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-960941","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSavara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference LANGHORNE, Pa.–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA) (the \u201cCompany\u201d), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference on Tuesday, May 19th at 10:00am ET in New York, NY at the NASDAQ headquarters. The live webcast and subsequent replay will be available on the \u201cEvents & Presentations\u201d section of the Company\u2019s corporate website and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant … Continue reading "Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-11T20:36:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260511376114r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference\",\"datePublished\":\"2026-05-11T20:36:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\\\/\"},\"wordCount\":282,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260511376114r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\\\/\",\"name\":\"Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260511376114r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-05-11T20:36:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260511376114r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260511376114r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference - Market Newsdesk","og_description":"Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference LANGHORNE, Pa.–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA) (the \u201cCompany\u201d), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference on Tuesday, May 19th at 10:00am ET in New York, NY at the NASDAQ headquarters. The live webcast and subsequent replay will be available on the \u201cEvents & Presentations\u201d section of the Company\u2019s corporate website and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant … Continue reading \"Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-11T20:36:18+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260511376114r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference","datePublished":"2026-05-11T20:36:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/"},"wordCount":282,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260511376114r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/","name":"Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260511376114r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-05-11T20:36:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260511376114r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260511376114r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/savara-announces-participation-in-the-h-c-wainwright-co-4th-annual-bioconnect-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/960941","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=960941"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/960941\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=960941"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=960941"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=960941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}